Safety profiles come to fore as more drugs approach MS market.
Cormac
C
Sheridan
D000074323:Alemtuzumab; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D017326:Clinical Trials, Phase III as Topic; D000069462:Dimethyl Fumarate; D017277:Drug Approval; D005650:Fumarates / Q000627:therapeutic use*; D006801:Humans; D009103:Multiple Sclerosis / Q000188:drug therapy*; D061214:Patient Safety
D061067:Antibodies, Monoclonal, Humanized; D005650:Fumarates; D000074323:Alemtuzumab; D000069462:Dimethyl Fumarate